Fecal microbiota transplantation for patients with refractory diarrhea after allogeneic hematopoietic stem cell transplantation.
10.3760/cma.j.issn.0253-2727.2019.10.011
- Author:
Qian WANG
1
;
Yue Wen FU
;
Yong Qi WANG
;
Hao AI
;
Fang Fang YUAN
;
Xu Dong WEI
;
Yong Ping SONG
Author Information
1. Department of Hematology, The Anti- Cancer Hospital Affiliated with Zhengzhou University, Zhengzhou 450008, China.
- Publication Type:Journal Article
- Keywords:
Diarrhea;
Fecal microbiota transplantation;
Graft versus host disease;
Hematopoietic stem cell transplantation
- MeSH:
Diarrhea/therapy*;
Fecal Microbiota Transplantation;
Graft vs Host Disease;
Hematopoietic Stem Cell Transplantation/adverse effects*;
Humans;
Leukemia, Myeloid, Acute
- From:
Chinese Journal of Hematology
2019;40(10):853-855
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore the availability and safety of fecal microbiota transplantation for patients with refractory diarrhea after allogeneic hematopoietic stem cell transplantation (allo-HSCT) . Methods: Four acute leukemia patients suffered from refractory diarrhea after allo-HSCT. One of them was refractory intestinal infection, the others were intestinal graft versus host disease. One or two doses of fecal microbiota, 3.4-6.0 U for one dose, were infused via nasal-jejunal tube. The curative effect and side effects were reviewed. Results: Three cases achieved complete remission while 1 was stable disease. The side effects included fever, abdominal pain and diarrhea, which all were Ⅰ grade. Conclusion: Fecal microbiota transplantation was effective and safe for refractory diarrhea after allo-HSCT.
